ClinicalTrials.gg
RecruitingNCT07219537Updated Dec 16, 2025

A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule

An interventional study of Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract in Lynch Syndrome, Crohn Disease and Inflammatory Bowel Diseases, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Mar 2023, registered Oct 2025).
  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 21 open to participants now, 33 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.

Planned enrollment
34th of 43
30 · median 162
Started
2023
with 6 others
No phase
28 of 72
9 open now
Primary completion
2027-12
later than 14 of 32 live
Registered
68th of 72
by date
Lead sponsor
2 of 72
Massachusetts General Hospital

Among the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 34th largest by planned enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2023, is one of 28 with no phase, reaches primary completion later than 14 of the 32 other live ones, and was the 68th registered.

Colorectal Neoplasms, Hereditary Nonpolyposis

147 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 61 are open to participants now.

Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →

Open to participants now

21 of the 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, or all of them as a file.
02

Study summary

The investigators have developed an inexpensive tool to take pictures in the lower GI tract without sedation and to look for signs of disease. The tool is a capsule, about the size of a fish oil or multi-vitamin supplement, attached to a string. The capsule and string are connected to a motor to allow the capsule to advance up the participant's lower GI tract. The capsule will be inserted into the participant's lower GI tract and advance upward via a slow spiral motion. The capsule is connected to an imaging system that saves and displays the images in real time.

03

Conditions studied

  • Lynch Syndrome
  • Crohn Disease
  • Inflammatory Bowel Diseases
  • Healthy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years of age or older.
  • Are healthy or with a confirmed diagnosis of Lynch Syndrome
  • Are capable of giving .
  • Are able to follow bowel prep instructions
  • Had a colonoscopy 0-24 months prior that did not show any abnormalities or individuals who report no gastrointestinal symptoms and no knowledge of any lower GI tract disease or abnormality and volunteer through Rally.

Exclusion criteria

Exclusion Criteria:

  • Who are over 75 years of age or older
  • With a history or current diagnosis of colonic and/or anal strictures
  • With a current diagnosis of any bleeding disorders
  • Who currently use drugs that interfere with coagulation (excluding low-dose aspirin)
  • With a history or current diagnosis of colorectal cancer
  • With a history or current diagnosis of diverticulosis or diverticulitis
  • With any prior anorectal, colorectal, or colonic surgery
  • With a history of volvulus or torsion
  • Who are pregnant
  • With to bowel prep or colonoscopy
  • With severe acute inflammatory bowel disease
  • With large hemorrhoids or hemorrhoidal bleeding or banding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Healthy

    20 healthy adult participants with no pre-existing gastrointestinal disorders will be enrolled at MGH.

    Device: Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract

  • Experimental
    With Disease

    10 adult participants with a confirmed diagnosis of Lynch Syndrome, Crohn's Disease, or Inflammatory Bowel Disease will be enrolled at MGH.

    Device: Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract

Interventions

  • DeviceFeasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract

    30 participants will be enrolled in this study. All consented participants will receive the same intervention.

06

What researchers measure

Primary outcomes

  1. Ability of the R-TCE capsule to acquire quality images of the lower GI tract

    Time frame: Imaging data is collected during the study procedure and analyzed within one year of collection.

Secondary outcomes

  1. Tolerability of the R-TCE Capsule in an unsedated participant

    R-TCE imaging will be conducted in unsedated participants. The study team will ask the participants about their comfort level throughout the procedure. Participants will be asked to score the tolerability of the procedure using a scoring system from 0 to 10. With 0 being the most tolerable to10 being the least.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.

Of 37 interventional studies with no phase under Colorectal Neoplasms, Hereditary Nonpolyposis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 86. This study's planned 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 22, 2025
StartActual
Mar 27, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07219537
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, Dana-Farber Cancer Institute
Responsible party
Guillermo Tearney (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Oct 22, 2025
Start date
Mar 27, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 16, 2025

Study contacts

Nitasha Bhat, M.D.
Contact
Tearneylabtrials@partners.org
617-643-6092
Guillermo Tearney, M.D., PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion